Page last updated: 2024-08-21

pyrazines and Hyperlipoproteinemia Type II

pyrazines has been researched along with Hyperlipoproteinemia Type II in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (14.29)	18.7374
1990's	6 (85.71)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chojnowska-Jezierska, J; Jabłoński, S; Tkaczewski, W	1
Kleinjans, HA; Stalenhoef, AF; Stuyt, PM	1
Bergemann, R; Brandt, A; Siegrist, W	1
Alcocer, L; Campos, E; Fernández, L; Más, R	1
Tornvall, P; Walldius, G	1
Bedford, DK; Gaw, A; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J	1
Avogaro, P; Crepaldi, G; Descovich, GC; Di Perri, T; Musatti, L; Postiglione, A; Sirtori, CR; Strano, A; Ventura, S	1

Trials

5 trial(s) available for pyrazines and Hyperlipoproteinemia Type II

Article	Year
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. The Netherlands journal of medicine, 1998, Volume: 53, Issue:5 Topics: Adult; Aged; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Safety; Simvastatin	1998
A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia. International journal of tissue reactions, 1999, Volume: 21, Issue:3 Topics: Aged; Anticholesteremic Agents; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Treatment Outcome	1999
A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability. Journal of internal medicine, 1991, Volume: 230, Issue:5 Topics: Adult; Blood Glucose; Female; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrazines	1991
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. British journal of clinical pharmacology, 1990, Volume: 30, Issue:1 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Patient Compliance; Pyrazines; Triglycerides	1990
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis, 1988, Volume: 70, Issue:1-2 Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrazines; Triglycerides	1988

Other Studies

2 other study(ies) available for pyrazines and Hyperlipoproteinemia Type II

Article	Year
[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1993, Volume: 46, Issue:9-10 Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Treatment Outcome	1993
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). PharmacoEconomics, 1993, Volume: 3, Issue:2 Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome	1993